Is the FDA finally loosening its grip on regenerative medicine?In this landmark episode, Donna Chang and Jan Shultis break down the major regulatory shakeups coming out of Washington—from the removal of CAR-T safety barriers to RFK Jr.’s sweeping promises to “clear the path” for innovation. With high-profile figures like Dr. Vinay Prasad and Dr. Carl June calling for less FDA oversight and faster approvals, it seems the tide is turning for cell and gene therapy pioneers.🔍 Topics We Cover:• Highlights from the June 5 CBER Roundtable• RFK Jr.'s new health leadership team and policy vision• Why Carl June wants early-stage CGT trials to skip FDA• Real-world impacts of the REMS removal for CAR-T• Why U.S. trials involving foreign labs are being halted• The rise of AI in drug approvals—helpful or dangerous?• The role of the new FDA Office of Therapeutic Products (OTP)• What it all means for autologous stem cell therapy💡 If you’re in the biotech, clinical research, or regenerative medicine space, this is essential listening. The rules are shifting—and your ability to deliver breakthrough therapies may finally get the green light.👇 Drop your thoughts in the comments:Is less regulation good for innovation? Or are we heading into risky territory?🔔 Subscribe for more episodes of the Stem Cell Revolution.📍 Produced by Hope BiosciencesLinks:WEBSITE - https://www.hope.bioINSTAGRAM -   / hope.bio  TWITTER -   / hopebiosciences  FACEBOOK -   / hopebiosciences  

#StemCellRevolution #RegenerativeMedicine #RFKjr #CAR_T #FDAupdates #CellTherapy #GeneTherapy #Autologous #CBER #HopeBiosciences